Therefore, the growing number of antimalarial and SCD drugs/vaccines that are under clinical development are expected to boost the market growth in the future. Increasing Prevalence of Malaria and Sickle Cell Disease to Bolster Malaria and Sickle Cell Disease Treatment Market Growth

According to our latest study on ” Malaria and Sickle Cell Disease Treatment Market Forecast to 2030 – Global Analysis –Treatment, Route of Administration, and Distribution Channel,” the market is expected to grow from US$ 4,691.87 million in 2022 to US$ 29,179.60 million by 2030; it is estimated to grow at a CAGR of 26.5% during 2022–2030. The market growth is primarily attributed to increasing prevalence of malaria and sickle cell disease and rising government initiatives to raise awareness about malaria and SCD. However, lack of sickle cell disease treatment options and the availability of counterfeit antimalarial drugs, followed by subsequent drug resistance are hindering the market growth.

Get Your Free Sample Copy Today | Click Here: https://www.theinsightpartners.com/sample/TIPRE00030125

Antimicrobial resistance can put the public at risk of many diseases, such as malaria. To overcome this challenge, the R&D of new medicines is considered the best strategy; as a result, the antimalarial and SCD drug/vaccine pipeline is becoming increasingly robust. Public-private partnerships are accelerating research activities related to the treatment of malaria and sickle cell disease. For instance, Medicines for Malaria Venture (MMV), a nonprofit organization, works with numerous pharmaceutical companies to reduce the burden of malaria by developing novel treatment options.

Malaria, one of the acute febrile illnesses, is caused by plasmodium parasites and spreads through the infected female Anopheles mosquitoes. Five parasite species in humans mainly cause malaria, and two of these species—Plasmodium falciparum and P. vivax—are considered the greatest threat to human health. Also, P. falciparum is the deadliest malarial parasite, and it is most widely spread across the African continent. Further, P. vivax is the dominant malarial parasite in most countries outside of sub-Saharan Africa. According to the latest World Malaria Report (WMR) 2020 from the World Health Organization (WHO), 241 million cases of malaria were reported in the world, in comparison to 227 million cases that were logged in 2019. According to the same source, the number of deaths caused due to malaria has an annual rise of 69,000 deaths. Approximately two-thirds of these deaths, i.e., 47,000, were caused by disruptions in healthcare services during the COVID-19 outbreak; the remaining one-third of deaths, i.e., 22,000 reflected a recent change in the WHO’s methodology for calculating malaria mortality (irrespective of COVID-19 disruptions).

The WHO African region accounted for a high share of the global burden of malaria. In 2020, ~95% of global cases and ~96% of deaths were reported in Africa due to malaria, and ~80% of the total deaths that were reported were in children aged 5 and below. According to the WHO, four African countries, Nigeria, Tanzania, the Democratic Republic of the Congo, and Mozambique, recorded approximately half of all malaria-related deaths that were reported globally. According to the LANCET Regional Health 2020, African countries had the highest burden of malaria; P. falciparum is a notable cause of the highest mortality rates in children younger than 5, which accounts for ∼77% across the world; in African countries, P. falciparum accounts for ∼96% of total mortalities caused among children by malaria. P. vivax has been a causal agent of 2% (4.5 million) of the total cases of malaria, mainly from Asia. According to WMR 2021, ∼2% of the global burden of malaria was recorded by Southeast Asian countries, where India accounted for 83% of estimated malaria cases and 82% of deaths associate with malaria in 2020.

The treatment plan for sickle cell disease (SCD) can be divided into two categories: maintaining health and treating complications. Sickle cell anemia has genotypic and phenotypic variants that are based on unique mutations in hemoglobin genes. There is a high prevalence of the disease as well as a rise in its severity across the globe. According to the WHO, approximately 5% of the world’s population has genes inhibiting hemoglobin diseases such as sickle cell anemia and thalassemia. According to a study on sickle cell disease published in the National Library of Medicine, more than 300,000 babies are born with severe hemoglobin disorders each year; also, 400,000 newborns are expected to have sickle cell disease by 2050. In addition, according to a published report in 2023 by the American Society of Hematology, the estimated number of people suffering from SCD in the US is approximately 70,000–100,000. Thus, the rising prevalence of malaria and sickle cell disease in different regions across the globe boosts the malaria and sickle cell disease treatment market growth.

Cipla Ltd, Pfizer Inc, Sun Pharmaceutical Industries Ltd, Sanofi SA, GSK Plc, Novartis AG, Pfizer Inc, Emmaus Life Sciences Inc, AdvaCare Pharma USA LLC, VLP Therapeutics LLC, and Lupin Ltd are among the leading companies operating in the malaria and sickle cell disease treatment market.

Based on treatment, the sickle cell disease treatment market is segmented into malaria and sickle cell disease (SCD). Based on route of administration, the sickle cell disease treatment market is bifurcated into oral and parenteral. Based on distribution channel, the sickle cell disease treatment market is divided into direct tender, hospital pharmacies, retail pharmacies, online pharmacies, and others. By geography, the sickle cell disease treatment market is segmented into North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (UAE, Saudi Arabia, Africa, Nigeria, Congo, Tanzania, Uganda, Ghana, Kenya, Zambia, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

About US

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Malaria and Sickle Cell Disease Treatment, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Food and Beverages, Consumers and Goods, Chemicals and Materials.

Contact US

Contact Person : Ankit Mathur

Phone : +1-646-491-9876

E-mail : [email protected]